A new trial will test a low-cost antibiotic in reducing deaths among 8 000 patients with advanced HIV who are starting or restarting anti-retroviral therapy (ART).
The Revive study, funded by the Bill & Melinda Gates Foundation, involves a pan-African network of investigators, co-led by researchers at UCT and the Population Health Research Institute (PHRI), a joint institute of McMaster University and Hamilton Health Sciences in Canada.
The trial aims to determine whether the antibiotic azithromycin, when taken once daily over four weeks, can reduce death in adults with advanced HIV. The study will span over 100 sites across a growing number of countries in Africa. Botswana, Ethiopia, Ghana, Ivory Coast, Malawi, Nigeria, the Republic of the Congo, Rwanda, Sierra Leone, South Africa, Tanzania, Uganda and Zambia, with more countries…